Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

von Willebrand disease type 2B - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

von Willebrand disease type 2B

MONDO:0015629

Also known as:von Willebrand disease, type 2B

Overview

A subtype of type 2 VWD characterized by a bleeding disorder associated with an increase in the affinity of the Willebrand factor (von Willebrand factor; VWF) for platelets. This anomaly results in spontaneous binding of high molecular weight VWF multimers to platelets leading to rapid clearance of both the platelets (increasing the risk of thrombocytopenia) and the high molecular weight VWF multimers from the plasma.

ResearchLimited published research (4 articles)

Diagnosis

Biomarker and diagnostic research for von Willebrand disease type 2B has been reported in the published literature.

Prognosis

Estimated prevalence: Unknown (Unknown prevalence).

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for von Willebrand disease type 2B.

4 publications have been identified in PubMed for von Willebrand disease type 2B. Research spans Diagnostic / Biomarker (50%), Basic Science / Preclinical (25%), and Gene Therapy / Novel Therapeutics (25%).

Recent Publications

Glonnegger H (2026). [PMID: 42082146](https://pubmed.ncbi.nlm.nih.gov/42082146/). *Hamostaseologie*. [Diagnostic / Biomarker]
Linthorst NA (2025). [PMID: 39820471](https://pubmed.ncbi.nlm.nih.gov/39820471/). *Blood advances*. [Gene Therapy / Novel Therapeutics]
Aslam S (2025). [PMID: 40462825](https://pubmed.ncbi.nlm.nih.gov/40462825/). *Cureus*. [Diagnostic / Biomarker]
Machha VR (2024). [PMID: 39719968](https://pubmed.ncbi.nlm.nih.gov/39719968/). *NAR molecular medicine*. [Basic Science / Preclinical]

Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 6:47 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:166087

GARD

Genetic and Rare Diseases Info Center

GARD:17022

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

von Willebrand disease type 2B

Overview

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team